Form 4: Pasithea Director Granted Stock Options

Pasithea Therapeutics Corp. Director Simon Dumesnil was granted 42,913 stock options with an exercise price of $0.715, vesting over one year.

Summary

• Simon Dumesnil, a Director of Pasithea Therapeutics Corp. (KTTA), was granted 42,913 stock options.
• The options have an exercise price of $0.715 per share.
• The grant date for these options was October 24, 2025.
• The options were awarded under the company's 2023 Stock Incentive Plan.
• The shares underlying the options will vest in full on the one-year anniversary of the grant date, October 24, 2026, provided Mr. Dumesnil remains a director.
• Full vesting will also occur upon a Change in Control as defined in the Plan.
• The options have an expiration date of October 23, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns the director's interests with shareholders and incentivizes long-term performance. It's a routine compensation event, not indicative of extraordinary positive or negative news, hence a moderately positive score.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages director retention and commitment to the company's strategic goals.
• The existence of a 2023 Stock Incentive Plan indicates a structured approach to executive and director compensation.

Negatives

• The issuance of new stock options, if exercised, could lead to a slight dilution of existing shareholders' equity, although the impact from this single grant is minimal.

Risks

• The value of the options is subject to the future market price of Pasithea Therapeutics Corp. common stock, which may not exceed the exercise price of $0.715.
• The options' vesting is contingent upon the reporting person remaining a director through the one-year anniversary of the grant date, posing a risk of forfeiture if employment terms change.
• The company's stock performance, and thus the options' intrinsic value, is subject to general market conditions and company-specific operational and financial risks.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's operational or financial performance, beyond the vesting schedule of the granted options.

Industry Context

The granting of stock options to directors is a standard practice across various industries, particularly in biotechnology and emerging growth companies like Pasithea Therapeutics, to attract, retain, and incentivize key personnel by aligning their financial interests with long-term shareholder value creation.

Comparison to Industry Standards

• The exercise price of $0.715, being the market price on the grant date, is a common practice for incentive stock options to ensure they are "at-the-money" at issuance.
• A one-year cliff vesting schedule is a relatively common, though sometimes considered aggressive, vesting period for director compensation, aiming for quick alignment. Many companies use multi-year vesting schedules (e.g., 3-4 years) for executive options.
• The ten-year expiration period (10/24/2025 to 10/23/2035) is standard for stock options, providing a long window for the options to become in-the-money.
• The provision for accelerated vesting upon a Change in Control is a typical feature in equity incentive plans, designed to protect the value of executive and director compensation in the event of an acquisition.

Corporate Governance

Related Party Transactions

• The grant of stock options to Simon Dumesnil, a director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options; improved alignment of director's interests with shareholder value creation.
• Employees: No direct impact mentioned for general employees, but the existence of a stock incentive plan suggests a broader framework for equity compensation.
• Directors: Provides a significant incentive for director retention and performance, linking their personal financial success to the company's stock performance.

Next Steps

• The options will vest in full on October 24, 2026, provided Simon Dumesnil remains a director.
• The options may vest earlier upon a Change in Control as defined in the Plan.
• Simon Dumesnil may choose to exercise the options at any time after vesting and before the expiration date of October 23, 2035.

Key Dates

Recommendation

This Form 4 filing reports a routine stock option grant to a director, which is a standard compensation practice. It does not contain any information that would fundamentally alter the investment thesis for Pasithea Therapeutics Corp. While it aligns director interests with shareholders, it's not a catalyst for significant price movement, thus a 'hold' recommendation is appropriate for existing investors, and it provides no new strong 'buy' or 'sell' signal.

Keywords

Pasithea Therapeutics, KTTA, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Incentive Plan, Beneficial Ownership